{
  "id": "fda_guidance_chunk_0475",
  "title": "Introduction - Part 475",
  "text": "3 A. The Non-Inferiority Hypothesis .................................................................................................... 3 B. Reasons for Using a Non-Inferiority Design ................................................................................ 7 C. The Non-Inferiority Margin .......................................................................................................... 8 D. Assay Sensitivity ........................................................................................................................... 11 E. Statistical Inference ..................................................................................................................... 14 F. Regulatory Conclusions ............................................................................................................... 15 G. Alternative Designs ...................................................................................................................... 16 H. Number of Studies Needed .......................................................................................................... 17 I. Choice of Active Control ............................................................................................................. 18 IV. CHOOSING THE NON-INFERIORITY MARGIN AND TESTING THE NON-INFERIORITY HYPOTHESIS .................................................................................... 19 A. Introduction .................................................................................................................................. 19 B. Statistical Uncertainties and Quantification of the Active Control Effect .............................. 20 C. Fixed Margin and Synthesis Methods ........................................................................................ 27 D. Considerations for Selecting the Clinical Margin (M2) ............................................................ 30 E. Estimating the Sample Size ......................................................................................................... 30 F. Study Quality and Choice of Analysis Population .................................................................... 31 G. Testing Non-Inferiority and Superiority in a Single Trial ....................................................... 31 V. FREQUENTLY ASKED QUESTIONS AND GENERAL GUIDANCE .................. 32 APPENDIX — EXAMPLES ...................................................................................................... 37 REFERENCES FOR EXAMPLES ........................................................................................... 48 REFERENCES ............................................................................................................................ 51 Contains Nonbinding Recommendations Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry1 This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page. I. INTRODUCTION This document provides guidance to sponsors and applicants submitting investigational drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate use of non-inferiority (NI) study designs to provide evidence of the effectiveness of a drug or biologic, usually because a superiority study design (drug versus placebo, dose response, or superiority to an active drug) cannot be used.2 The guidance gives advice on when NI studies intended to demonstrate effectiveness of an investigational drug can provide interpretable results, how to choose the NI margin, and how to test the NI hypothesis. This guidance does not provide recommendations for the use of NI study designs to evaluate the safety of a drug. In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency’s current thinking on a topic and should be viewed only as recommendations,",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 637056,
  "end_pos": 638592,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "design",
    "statistical",
    "regulatory",
    "clinical_trial",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.714Z"
}